POST Online Media Lite Edition


Perrigo completes divestiture of generic Rx business for $1.55 billion

Christian Fernsby |
Perrigo announced that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion, with customary adjustments.

Article continues below

Topics: PERRIGO   

Perrigo CEO and President Murray S. Kessler commented, "Closing this transaction was another important milestone for Perrigo's transformation.

"We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality – To make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company's future."

Kessler concluded, "I would like to thank the Rx team for their dedication throughout this process and I am confident that they will continue to be successful in their mission of developing, manufacturing and distributing high quality, affordable healthcare products."

What to read next

Perrigo and Elan have all approvals to merge
FTC sues Endo Pharmaceuticals, 7 others for blocking lower-cost generics
Perrigo CEO to Mylan: All your statements are false